SAFETY, TOLERANCE, AND EFFICACY OF ATEVIRDINE IN ASYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS

Authors
BEENTIKTAK AMM WILLIAMS I VREHEN HM RICHENS J ALDAM D VANLOON AM LOVEDAY C BOUCHER CAB WARD P WELLER IVD BORLEFFS JCC
Citation
Amm. Beentiktak et al., SAFETY, TOLERANCE, AND EFFICACY OF ATEVIRDINE IN ASYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS, Antimicrobial agents and chemotherapy, 40(11), 1996, pp. 2664-2668
Citations number
22
Categorie Soggetti
Pharmacology & Pharmacy",Microbiology
Journal title
Antimicrobial agents and chemotherapy → ACNP
ISSN journal
00664804
Volume
40
Issue
11
Year of publication
1996
Pages
2664 - 2668
Database
ISI
SICI code
0066-4804(1996)40:11<2664:STAEOA>2.0.ZU;2-M
Abstract
Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infe cted patients with CD4(+) cell counts of between 200 and 750 cells per mm(3). Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p2 4 antigen and HIV-1 RNA levels by PCR) or CD4(+) cell counts. The data do not support the use of atevirdine as a monotherapy in the treatmen t of HIV-infected patients.